GRAIL, Inc. (GRAL) vs GeneDx Holdings Corp. (WGS)
GRAIL, Inc. and GeneDx Holdings Corp. are both Diagnostics & Research companies. GRAIL, Inc. is the larger, with a market value of $5.5B against $2.6B — 2.1× the size. GeneDx Holdings Corp. grew revenue faster over the last twelve months: 25.4% against 23.1%. GeneDx Holdings Corp. has the higher net margin (−23.4% vs −237.0%) and the lower return on invested capital (−27.7% vs −20.8%). Across the 17 metrics below, GeneDx Holdings Corp. leads on 10 and GRAIL, Inc. on 7.
Valuation
Profitability
| Metric | GRAL | WGS | Diagnostics & Research median |
|---|---|---|---|
| Gross margin | (31.31%) | 69.37% | 50.89% |
| Operating margin | (338.40%) | (20.34%) | (8.57%) |
| Net margin | (236.95%) | (23.40%) | (6.37%) |
| Free cash flow margin | (179.21%) | (16.68%) | 0.00% |
| Return on equity | (16.12%) | (40.80%) | (2.92%) |
| Return on assets | (14.12%) | (22.50%) | (6.71%) |
| Return on invested capital | (20.79%) | (27.70%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack